Mayabeque, Cuba: Experts from the Finlay Vaccines Institute and the Pedro Kourí Tropical Medicine Institute, as well as the Mayabeque Faculty of Medical Sciences, are beginning studies to evaluate the effectiveness of the Soberana 02 vaccine.
This research of high scientific value revolves around the effectiveness and reactogenicity of the Cuban anticovid immunogen.
The principal investigator of the clinical trials of the drug, Dr. María Eugenia Toledo, specifies that they hope to have a sustainable control strategy in terms of reducing cases, especially in children.
They also hope that, given the appearance of new strains of the virus in the world, Cuba will be able, with its mass vaccination strategy, to maintain low contagion indicators and reduce mortality.
Indira La O Herrera
Periodista en Radio Mayabeque
